TB Alternative Assets Ltd. Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

TB Alternative Assets Ltd. purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 70,800 shares of the company’s stock, valued at approximately $706,000.

Several other hedge funds also recently modified their holdings of RXRX. Swiss National Bank boosted its stake in shares of Recursion Pharmaceuticals by 1.6% during the 3rd quarter. Swiss National Bank now owns 284,100 shares of the company’s stock worth $2,173,000 after purchasing an additional 4,600 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter worth approximately $117,000. Charles Schwab Investment Management Inc. boosted its position in shares of Recursion Pharmaceuticals by 15.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock worth $8,858,000 after acquiring an additional 157,189 shares during the last quarter. UBS Group AG boosted its position in shares of Recursion Pharmaceuticals by 103.1% in the third quarter. UBS Group AG now owns 342,679 shares of the company’s stock worth $2,621,000 after acquiring an additional 173,954 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Recursion Pharmaceuticals by 15.4% in the third quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock worth $457,000 after acquiring an additional 7,973 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $8.82, for a total value of $100,962.54. Following the completion of the sale, the director now owns 7,241,308 shares in the company, valued at $63,868,336.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total value of $26,340.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $8.82, for a total transaction of $100,962.54. Following the completion of the transaction, the director now directly owns 7,241,308 shares of the company’s stock, valued at approximately $63,868,336.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 281,359 shares of company stock worth $2,410,876. Insiders own 15.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday. KeyCorp raised their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th.

Recursion Pharmaceuticals Stock Down 6.6 %

Shares of RXRX traded down $0.62 during mid-day trading on Wednesday, reaching $8.76. 5,247,778 shares of the stock traded hands, compared to its average volume of 5,943,834. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -5.51 and a beta of 0.86. The stock has a fifty day simple moving average of $8.81 and a 200 day simple moving average of $9.94. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.34) earnings per share. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.